If you have been reading about obesity research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
When injected into the base of the penis, alprostadil may cause penile pain, dizziness, headache, high blood pressure, Peyronie disease, and burning at the injection site. When inserted into the urethra, alprostadil may cause urethral burning, penile pain, dizziness, headache, and urethral bleeding. When someone engages in vaginal sex after using an alprostadil urethral suppository, their partner may experience vaginal itching. Clinical trials for the treatment showed positive results in around 3,000 men that it was tested on; it is said to be usable by men with diabetes or heart problems and those who have undergone a prostatectomy.
The longest Romanian word is pneumonoultramicroscopicsilicovolcaniconioză, with 44 letters, (meaning "pneumonultramicroscopicsilicovolcanoconiosis") but the longest one admitted by the Dicționarul explicativ al limbii române ("Explanatory Dictionary of the Romanian Language", DEX) is electroglotospectrografie, with 25 letters.
==== Protein purification ==== Knowledge of an enzyme's resistance to high temperatures is especially beneficial in protein purification. In the procedure of heat denaturation, one can subject a mixture of proteins to high temperatures, which will result in the denaturation of proteins that are not thermostable, and the isolation of the protein that is thermodynamically stable. One notable example of this is found in the purification of alkaline phosphatase from the hyperthermophile Pyrococcus abyssi. This enzyme is known for being heat stable at temperatures greater than 95 °C, and therefore can be partially purified by heating when heterologously expressed in E. coli. The increase in temperature causes the E. coli proteins to precipitate, while the P. abyssi alkaline phosphatase remains stably in solution.
Sources: en.wikipedia.org
=== Diversification and decline === The ensuing financial crisis prompted a major strategic transition. In 1970, HVEC's losses represented 31 percent of total stockholder investment. The company laid off 100 employees and suspended many research programs, citing insufficient federal funding for basic physics research. That year also marked a leadership transition: Pascal Levesque, head of the profitable HVEC subsidiary Electronized Chemicals Corporation, became president and chief executive, while departing president Denis Robinson assumed the chairmanship held by Trump. Under new management, HVEC diversified into industrial applications of its accelerator technologies. By 1972, the company had reorganized as a miniconglomerate with more than ten subsidiaries manufacturing plastics, power equipment, and radiation processing systems—products enabled by particle accelerators rather than particle accelerators themselves. The diversification strategy yielded several commercially successful products. Electronized Chemicals Corporation's heat-shrink tubing, made by electron-beam crosslinking of polyethylene, became ubiquitous in electrical wiring. The technology enabled modern wire harnesses in automobiles and aircraft, where compact, reliable insulation was essential. Ion Physics Corporation introduced radiation-based ion implantation, enabling precise control of transistor characteristics in integrated circuits. HVEC closed Ion Physics in 1971, but became standard practice throughout the global semiconductor industry by the late 1970s.
=== Pipelines === South Africa's pipeline freight sector is the smallest of the country's freight modes by network size. However, pipelines are of strategic importance, as they continuously transport energy products between refineries, ports, storage depots, and major inland markets. These products include natural gas, crude oil, and refined petroleum products such as gasoline, diesel, paraffin, and jet fuel. Fuel pipelines in SA are predominantly managed by Transnet Pipelines (TPL), a division of state-owned company Transnet. Two other players in the sector are the Republic of Mozambique Pipeline Investments Company (ROMPCO), which owns and operates the 865km Mozambique to South Africa natural gas pipeline, and Sasol, which owns and operates portions of the downstream gas transmission network that distribute gas after it reaches Secunda via ROMPCO. At Secunda, Sasol operates the world's largest coal-to-liquids plant. The pipelines exists in large part to supply inland fuel demand, especially in Gauteng, without relying solely on road tankers or rail tank wagons. Major metros such as Cape Town and Durban are able to acquire their fuel by sea. The network of pipelines also supplies natural gas to KwaZulu-Natal. They span the provinces of KwaZulu-Natal, Free State, Mpumalanga, Gauteng, and North West. As of 2026, the network consists of:
=== Camille Braverman === Camille Braverman (Bonnie Bedelia) is the matriarch of the family and Zeek's wife. She is an artist and also shows herself to be very capable domestically, striving to keep her family happy and peaceful. In season one, when Zeek reveals that he made a bad investment that he kept from Camille, she reveals that he was having an affair. Zeek later reveals that they both cheated. Camille confirms to her daughter, Sarah, that she has been having an affair with her art teacher, Matthew, but that she has ended it. In season one, it is stated that she has been married to Zeek for 46 years. She is 63 when the series begins, meaning she was about 17 when she married Zeek. She was 23 when she had Adam, 25 when she had Sarah, 28 when she had Crosby, and 31 when she had Julia. After Zeek's death, she is shown as having traveled to France, to the place where Zeek had planned to take her as a surprise in an earlier episode. As she is shown in other scenes in the finale's final montage, she returns from her trip at some unknown point.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.